Filter Results :

Your search for Obesity returned 71 reports

Sort by


Abdominal Obesity-Pipeline Insights, 2015

01 Apr 2015  |  Published by:  DelveInsight
SUMMARYDelveInsight’s, “ Abdominal Obesity-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this Abdominal Obesity. A key objective of DelveInsight’s report is to establish the understanding for all the pipeline drugs that fall under Abdominal Obesity. T...

$ 1,250.00

Read More

Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

01 Apr 2015  |  Published by:  DelveInsight
SummaryDelveInsight’s, Obesity-API Insights, 2015,report provides Obesity drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related t...

$ 1,250.00

Read More

Obesity - Pipeline Review, H1 2015

10 Feb 2015  |  Published by:  Global Markets Direct
Summary‘Obesity - Pipeline Review, H1 2015’, provides an overview of the Obesity’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism o...

$ 2,000.00

Read More

Anti-Obesity Drugs Markets in China

01 Dec 2014  |  Published by:  Asia Market Info and Dev Co.
China's demand for Anti-Obesity Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & e...

$ 4,000.00

Read More

Global Anti-Obesity Drugs Market 2015-2019

26 Nov 2014  |  Published by:  Technavio
About ObesityObesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.Analy...

$ 2,500.00

Read More

Obesity Partnering 2009-2014

01 Nov 2014  |  Published by:  CurrentPartnering
Obesity Partnering 2009-2014 report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies. •Trends in obesity partnering deals •Top obesity deals by value •Deals listed by company A-Z, industry sector, stage ...

$ 995.00

Read More

Obesity - Pipeline Review, H2 2014

30 Sep 2014  |  Published by:  Global Markets Direct
Summary‘Obesity - Pipeline Review, H2 2014’, provides an overview of the Obesity’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism o...

$ 2,000.00

Read More

Physician Views: A post-AdCom assessment of Novo Nordisk's liraglutide for obesity

17 Sep 2014  |  Published by:  FirstWord
Novo Nordisk took an important step in its bid to enter the obesity market last week, when an FDA Advisory Committee voted 14-1 in favour to approve a 3mg version of its diabetes treatment liraglutide for this indication. This outcome reflects validation of the efficacy profile demonstrated b...

$ 645.00

Read More

Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) - Global Forecast to 2023

10 Sep 2014  |  Published by:  MarketsandMarkets
Report Description Need for early diagnosis and efficient treatment with microbiome therapy for maintaining healthy lifestyle will boost the human microbiome market. The product segment is expected to account for the largest share of the human microbiome market in the coming years. The hig...

$ 4,650.00

Read More

Obesity- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

01 Aug 2014  |  Published by:  DelveInsight
Summary'Obesity- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers f...

$ 2,000.00

Read More

Abdominal Obesity Global Clinical Trials Review, H1, 2014

05 May 2014  |  Published by:  GlobalData
Summary“Abdominal Obesity Global Clinical Trials Review, H1, 2014" provides data on the Abdominal Obesity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitm...

$ 2,500.00

Read More

Physician Views: What opportunity for Novo Nordisk's Victoza in obesity?

19 Nov 2013  |  Published by:  FirstWord
Analysts have notably mixed opinions on the commercial opportunity, but one of the more intriguing near-term catalysts for Novo Nordisk is potential FDA approval of Victoza (its GLP-1 anti-diabetic) for the treatment of obesity. Most recent Phase III data – published in May – supports a conse...

$ 645.00

Read More

Velneperit (Obesity) - Forecast and Market Analysis to 2022

31 Oct 2013  |  Published by:  GlobalData
SummaryAfter a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regula...

$ 3,495.00
$ 2,621.25
( Save 25% )

Read More

Oblean (Obesity) - Forecast and Market Analysis to 2022

31 Oct 2013  |  Published by:  GlobalData
SummaryAfter a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regula...

$ 3,495.00
$ 2,621.25
( Save 25% )

Read More

PharmaPoint: Obesity - Japan Drug Forecast and Market Analysis to 2022

31 Oct 2013  |  Published by:  GlobalData
SummaryAfter a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regula...

$ 4,995.00
$ 3,746.25
( Save 25% )

Read More
Total 71 records.